These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17357565)

  • 21. Superantigens: microbial agents that corrupt immunity.
    Llewelyn M; Cohen J
    Lancet Infect Dis; 2002 Mar; 2(3):156-62. PubMed ID: 11944185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical usefulness of intravenous human immunoglobulins in invasive group A Streptococcal infections: case report and review.
    Lamothe F; D'Amico P; Ghosn P; Tremblay C; Braidy J; Patenaude JV
    Clin Infect Dis; 1995 Dec; 21(6):1469-70. PubMed ID: 8749635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome.
    Stevens DL
    Clin Infect Dis; 1998 Mar; 26(3):639-41. PubMed ID: 9524836
    [No Abstract]   [Full Text] [Related]  

  • 24. Toxic shock syndrome: characterization of human immune responses to TSST-1 and evidence for sensitivity thresholds.
    Kimber I; Nookala S; Davis CC; Gerberick GF; Tucker H; Foertsch LM; Dearman RJ; Parsonnet J; Goering RV; Modern P; Donnellen M; Morel J; Kotb M
    Toxicol Sci; 2013 Jul; 134(1):49-63. PubMed ID: 23640863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comment on: Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.
    Rajagopalan G; Patel R; Kaveri SV; David CS
    J Antimicrob Chemother; 2007 Jan; 59(1):157-9; author reply 159-60. PubMed ID: 17071954
    [No Abstract]   [Full Text] [Related]  

  • 26. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease.
    Matsubara K; Fukaya T; Miwa K; Shibayama N; Nigami H; Harigaya H; Nozaki H; Hirata T; Baba K; Suzuki T; Ishiguro A
    Clin Exp Immunol; 2006 Mar; 143(3):427-34. PubMed ID: 16487241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapeutics targeting immune activation by staphylococcal superantigens.
    Krakauer T
    Med Sci Monit; 2005 Sep; 11(9):RA290-5. PubMed ID: 16127375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.
    Sriskandan S; Ferguson M; Elliot V; Faulkner L; Cohen J
    J Antimicrob Chemother; 2006 Jul; 58(1):117-24. PubMed ID: 16670109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case report: streptococcal toxic shock syndrome presenting as septic thrombophlebitis in a child with varicella.
    Cohen-Abbo A; Harper MB
    Pediatr Infect Dis J; 1993 Dec; 12(12):1033-4. PubMed ID: 8108215
    [No Abstract]   [Full Text] [Related]  

  • 30. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.
    Bohach GA; Fast DJ; Nelson RD; Schlievert PM
    Crit Rev Microbiol; 1990; 17(4):251-72. PubMed ID: 2206394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell response to superantigen restimulation during menstrual toxic shock syndrome.
    Rasigade JP; Thomas D; Perpoint T; Peyramond D; Chidiac C; Etienne J; Vandenesch F; Lina G; Ferry T
    FEMS Immunol Med Microbiol; 2011 Aug; 62(3):368-71. PubMed ID: 21492259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dilemmas in the treatment of invasive Streptococcus pyogenes infections.
    Stevens DL
    Clin Infect Dis; 2003 Aug; 37(3):341-3. PubMed ID: 12884157
    [No Abstract]   [Full Text] [Related]  

  • 33. Toxic shock syndrome: major advances in pathogenesis, but not treatment.
    Low DE
    Crit Care Clin; 2013 Jul; 29(3):651-75. PubMed ID: 23830657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superantigens in dermatology.
    Macias ES; Pereira FA; Rietkerk W; Safai B
    J Am Acad Dermatol; 2011 Mar; 64(3):455-72; quiz 473-4. PubMed ID: 21315950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Streptococcal toxic shock syndrome or Kawasaki disease? Two case studies of children with group A streptococcal pneumonia empyema].
    Bosland A; Arlaud K; Rousset-Rouvière C; Fouilloux V; Paut O; Dubus JC; Bosdure E
    Arch Pediatr; 2011 Dec; 18(12):1310-4. PubMed ID: 22041597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock.
    Arad G; Hillman D; Levy R; Kaempfer R
    J Leukoc Biol; 2001 Jun; 69(6):921-7. PubMed ID: 11404377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kawasaki syndrome: role of superantigens revisited.
    Leung DYM; Schlievert PM
    FEBS J; 2021 Mar; 288(6):1771-1777. PubMed ID: 32770775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Superantigens and antigen recognition of T lymphocytes].
    Gülmezoğlu E
    Mikrobiyol Bul; 1993 Apr; 27(2):164-70. PubMed ID: 8502189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [IgG antibodies against toxic shock syndrome toxin 1 in human immunoglobulins].
    Dickgiesser N; Kustermann B
    Klin Wochenschr; 1986 Jul; 64(14):633-5. PubMed ID: 3762013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel toxic shock syndrome toxin-1 amino acids required for biological activity.
    Brosnahan AJ; Schaefers MM; Amundson WH; Mantz MJ; Squier CA; Peterson ML; Schlievert PM
    Biochemistry; 2008 Dec; 47(49):12995-3003. PubMed ID: 19012411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.